We’re in a psychedelic renaissance. Rather than using Selective Serotonin Reuptake Inhibitors (SSRIs) to manage symptoms, a new approach at Field Trip Health is trying to get to the root causes of mental health conditions. Field Trip Health co-founder and chief clinical officer Ryan Yermus and Field Trip Health VP of healthcare practice Matt Emmer are working together to use psychedelic medicine, like ketamine, and trained therapists as an alternative to SSRIs in treating mental health conditions in order to transform this field of medicine. Their innovative approach to mental health treatment is also reflected in their development of novel molecule FT-104, which offers the promise of a shorter, guided psychedelic trip, allowing for the experience to be more accommodative for patients, and widens the landscape for business development due to its proprietary nature. Interviewed by Ash Bennington on October 29, 2021.